ID   GM06225
AC   CVCL_4N47
DR   CLO; CLO_0023143
DR   Coriell; GM06225
DR   Wikidata; Q54842229
RX   CelloPub=CLPUB00447;
RX   PubMed=30471880;
CC   Population: Jewish.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Cell type: Fibroblast of skin; CL=CL_0002620.
DI   NCIt; C84798; Kearns-Sayre syndrome
DI   ORDO; Orphanet_480; Kearns-Sayre syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_4N46 ! GM06224
SX   Male
AG   10Y
CA   Finite cell line
DT   Created: 22-09-15; Last updated: 29-06-23; Version: 9
//
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In misc. document) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda; USA (1992).
//
RX   PubMed=30471880; DOI=10.1016/j.kint.2018.08.038; PMCID=PMC6389356;
RA   Johnson S.C., Martinez F., Bitto A., Gonzalez B., Tazaerslan C.,
RA   Cohen C., Delaval L., Timsit J., Knebelmann B., Terzi F., Mahal T.,
RA   Zhu Y.-Z., Morgan P.G., Sedensky M.M., Kaeberlein M., Legendre C.,
RA   Suh Y., Canaud G.;
RT   "mTOR inhibitors may benefit kidney transplant recipients with
RT   mitochondrial diseases.";
RL   Kidney Int. 95:455-466(2019).
//